2018/12/07 For BIOHAL investors, 2nd Crowdsale has been extended.
Bio Authentication protocol
BIOHAL OPEN NETWORK is a decentralized preventive medicine platform with liquid biopsy authentication protocol that enables secure and transparent exchange and usage of a variety of medical data.
As liquid biopsy experts, we are having an extremely difficult time to know the fact that most people recognized their cancer at stage 1 to 4, needed an emergency surgery or already cannot be cured.
Our mission is to eliminate that situation and find their disease at stage 0.
Standardize and enable comprehensive medical data to authentication to access over the blockchain.
Decentralize the access layer and automate secure authentication for users
Increase the survival rate and Quality of life by early detection system
Enable people around the world to take free liquid biopsy test and overcome their potential diseases.
BIOHAL OPEN NETWORK is a free, open-source, blockchain based biometrics authentication protocol featuring the reliable and secure architecture of Biometrics: Smart contracts that utilize liquid biopsy test as known as PROTEO.
Our dried serum technology solves!
There are international regulations on every means of transportation of infectious substances (air, rail, road and marine transport as well as mail). The UN model rules are reflected in the international laws through the international model agreements.
We have invented the dried serum technology by separating serum from the blood as a way to solve these problems.
This enables safe transport of dried serum.
By enabling transport of dried serum, it is possible to perform a stable test
whose accuracy is not adversely affected by the condition of transportation.
BIOHAL OPEN NETWORK is a Biotech Decentralized Solution, Powered by Blockchain & PON Tokens
BIOHAL OPEN NETWORK by design is a platform which allows not only processing of clinical trials data but also support for researchers during R&D phase and marketplace for all types of market participants involved in clinical trials as well as direct sales of final biotech products to customers (patients).
BIOHAL is a competitive blockchain platform and the quality of being scalable.
|Focused on working with DApp|
|Bio Authentication Protocol|
|Liquid Biopsy Product|
|Disease Early Detection|
|Secured health records|
The Data stored in the public blockchain BIOHAL OPEN NETWORK will be the basis of the evidence base.
The ability to “scientific research” in a secure format using encrypted key in blockchain ecosystem
Global access to the accumulated array of information through an open API interface with the functionality required to analyze the available data.
A single blockchain platform for collecting, storing and analyzing information methods of diagnosis and treatment of cancer
The possibility of connecting an AI to search for “patterns” for developing new methods of cancer treatment
Usage through interaction within the ecosystem of patients, researchers, Regulator, CRO, pharmaceutical companies, clinics
Sponsors / Investors
National Ethical Committees
Contract research organizations (CRO)
Innovative Precision Medicine and Blockchain technology company specializing in the development of liqud biopsy for early diagnosis of cancer and monitoring the efficacy of cancer treatment
PROTEO is a liquid biopsy developed and ready.
PROTEO is the liquid biopsy technology which can theoretically detect the very early cancer of approx. 1 mm, and it has obtained an international patent for measuring a nucleosome. PROTEO has been successful in detecting molecular-level cancerﾓ for the first time in the world.
This is the only test method that can quantify the amount of cancer-related substances.
This is the only test method that can conduct cancer examination for a wide range of age from the infant (childhood cancer) to the elderly.
Samples can be sent to the medical laboratory via international mail; therefore, the area the international mail covers is the target area for this test. This means that its potential demand can be the whole worldﾕs population of 7.6 billion people.
Very early detection of cancer
from stage 0 (treatment is effective).
(very little physical distress).
No medical radiation exposure (safe for those who are pregnant or with possibility of pregnancy).
No fasting or diet restriction required before the test. (can be tested any time)
Blood sample taken at home with self-testing kit (can eliminate disparities in quality of health care).
If a test method that can quantitatively and quickly detect cancer-related or Alzheimer-related substances from blood components is developed, it can contribute not only to treatmentof cancer and Alzheimer but also greatly to reduction of medical expense worldwide.
As PROTEO is known as being applied not only cancer, but also other diseases such as Alzheimer dementia, Arthritis, and so on, PROTEO technology is the key role on this Open network.
The technology of PROTEO has been successful in basic research and clinical trials, and the results have been published, including the following.
Nanotechnology, Biology, and Medicine"
"Royal Society of Chemistry"
Liquid biopsy is ideal as it is minimally invasive;
however, it has not been implemented for practical use despite the fact that it has been known as cancer markers in the research publications of exosomes, circulating tumor cells (CTCs), and circulating tumor DNA (ctDNA).
These marker substances begin to be inactivated as soon as they are taken out of blood. It is also unsuitable for quantitative detection since it is terribly difficult to directly extract the target substance only because the available amount in the blood is extremely small. Moreover, it has been kept away from practical use since the protocol up to the detection is complex and requires a long period of time.
Cancer early detection by the liquid biopsy is attracting more attention than ever.
According to a marketing research company, the market size is rapidly growing and estimated in the size of 10 billion US dollars annually.
Piper Jaffray companies, an investment bank reports that field by liquid biopsy is already being developed by 38 companies.
Analysts predicted the market size of the genetic screening by liquid biopsy will be from 20 billion to 40 billion US dollars in USA.
Cancer annually globally
PROTEO Tests only
M&A deals on medical market
during each of the last 3 years
1 PON = 0.06 USD
1 PON = 0.10 USD
ETH, BTC, XRP
2018 - 2023
1st Quater, 2018
Started decentralized medical blockchain project
2nd Quater, 2018
Started to develop Demo app with Bio medical protocol
3rd Quater, 2018
BIOHAL ICO Launched
3rd Quater, 2018
Bio Authentication Dapp(β）
2nd Quater, 2019
Establish the new Liquid Biopsy Labs
2nd Quater, 2019
Release BIOHAL Open Network α
JSPCM：Japan Society of Preemptive and Clinical Medicine/ Chairman JSCSF：Japan Society of Clinical Study for Frontier-Medicine/Vice Chairman
Now people want that their personal future health conditions could be detectable by a risk screening from the stage the potential diseases that not appear yet.
BIOHAL will realize the desire.
Chairman: Foundation for Kobe International Medical Alliance
Professor and Director: Laboratory of Cell and Gene Therapy
Institute for Advanced Medical Sciences
JSPCM：Japan Society of Preemptive and Clinical Medicine/ Vice Chairman
Patients, doctors, hospitals, pharmaceutical companies, etc. need to cooperate more than ever. Therefore, the data between them can be connected through BIOHAL blockchain as the best architecture.
Yorozu Clinic / President JSCSF：Japan Society of Clinical Study for Frontier-Medicine Director The Association for Clinical Research of Fecal Microbiota Transplantation Japan Managing Director
How can we better support our patients? For that purpose,early detection of disease and appropriate treatment suitable for that person are more important than anything. BIOHAL not only makes it possible, everyone in the world can take inspections.
President & Founder Dave Law Group, LLC / Patent Attorney of in the United States Gujarat Council on Science and Technology (GUJCOST) Chair Professor for IPR Excellence at Gujarat National Law University (GNLU).
Although science and technology has advanced dramatically, human being have to be alive with diseases. An innovative architecture, BIOHAL could save people from the sufferings and anxiety of the diseases. Everyone would want it. I am also one of them. I wish for the happiness of people, I will join in this project.
I always think about a life of human being. And I also think how I can help people in the world. As I have developed the best laboratory procedure at that time for most of my life, I would like to save lives of people by the procedure as much as I can. BIOHAL can make it possible.
President: Fukuyama Medical Laboratory
Because everyone in the world can take an inspection by BIOHAL ecosystem which can detect a disease at early stage.The earlier you concentrate on treatment, the less burden of disease you have. And your family can contribute your energy to society.This new approach will be a savior for people all over the world.